"VSports最新版本" Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults
- PMID: 17485150
- DOI: 10.1016/j.vaccine.2007.04.008
"VSports手机版" Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults
V体育官网 - Abstract
Two double-blind randomised controlled studies (phase I and I/II) were performed to assess for the first time the safety and immunogenicity of a recombinant subunit gp350 Epstein-Barr virus (EBV) vaccine in 148 healthy adult volunteers. All candidate vaccine formulations had a good safety profile and were well tolerated, with the incidence of solicited and unsolicited symptoms within a clinically acceptable range. One serious adverse event was reported in the phase I trial which was considered to be of suspected relationship to vaccination. The gp350 vaccine formulations were immunogenic and induced gp350-specific antibody responses (including neutralising antibodies) VSports手机版. .
"V体育ios版" Publication types
- "VSports手机版" Actions
- "V体育ios版" Actions
V体育安卓版 - MeSH terms
- "V体育官网入口" Actions
- VSports app下载 - Actions
- "V体育官网" Actions
- V体育安卓版 - Actions
- "V体育官网" Actions
- "VSports最新版本" Actions
- VSports app下载 - Actions
- Actions (VSports app下载)
Substances
- "VSports注册入口" Actions
- "V体育官网入口" Actions
- "V体育官网入口" Actions
LinkOut - more resources
Full Text Sources
"VSports注册入口" Other Literature Sources
